Clinical Trials
11 trialsNCT05004350 2026-04-30
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT05510895 2025-10-01
NeoBRAF
AIO-Studien-gGmbH
Phase 2 Completed
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT01894672 2024-07-16
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02631447 2024-06-07
SECOMBIT
Fondazione Melanoma Onlus
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03693170 2024-02-02
ANCHOR-CRC
Pierre Fabre Medicament
Phase 2 Completed
NCT02834364 2023-11-24
GMMG-BIRMA
University of Heidelberg Medical Center
Phase 2 Completed
NCT01719380 2021-06-23
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Pfizer
Phase 2 Completed